NCT02532868 2015-08-26
A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)
Merck Sharp & Dohme LLC
Phase 1 Terminated
Clinical Trials
5 trialsNCT00111683 2015-08-25
MK0457 in Patients With Leukemia (0457-003)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00290550 2015-07-27
A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00500006 2015-01-30
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00405054 2015-01-26
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
Merck Sharp & Dohme LLC
Phase 2 Terminated